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patients with type 2 diabetes mellitus (T2DM). This study explored the association 
of race/ethnicity and gender with complications severity, HRU, and costs among 
Medicare Advantage patients. Methods: A retrospective cohort study was per-
formed using medical and pharmacy claims of 333,576 Medicare members enrolled 
from 1/1/2010 to 12/31/2011, aged 18 to 89, and with ≥ 1 medical claim with primary 
diagnosis or ≥ 2 medical claims with secondary diagnosis of T2DM (ICD-9-CM 250.
x0 or 250.x2). Complications severity was assessed with the Diabetes Complications 
Severity Index, with scores of 0 (no complications) through 5+ (five or more). HRU 
was reported by mean (standard deviation [SD]) number of outpatient, inpatient, 
and emergency room [ER] visits. Costs were reported as means (SD) of medical, 
pharmacy and total health care costs evaluated. Associations of race/ethnicity and 
gender with the three outcomes were evaluated using generalized linear regression 
models. Results: The sample was older (70.81 ±8.8 years) and 80% White. Being 
Hispanic, Black, or male was associated with a higher prevalence of more severe 
T2DM complications; this disparity was more pronounced among females, with 
the odds of having more severe complications being higher for Hispanic and Black 
females compared to White females (Hispanic v. White odds ratio [OR], 1.40; 95% 
confidence interval [CI], 1.32-1.48), and (Black v. White OR, 1.22; 95% CI, 1.19-1.25). 
Regardless of gender, Blacks had more ER visits than Whites. Whites, particularly 
females, incurred the highest total annual health care costs, (White female costs: 
$13,086; 95% CI, $12,935-$13,240) vs. (Hispanic female costs: $10,732; 95% CI, $10,406-
$11,067). ConClusions: Racial/ethnic and gender differences exist in certain T2DM 
clinical and economic outcomes. Following these specific patients’ progress more 
closely may prevent or delay complications and decrease long term costs
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objeCtives: Eclampsia remains a major cause of maternal morbidity and mortal-
ity worldwide. In underdeveloped countries, the mortality rate is even higher due 
to the poor access to the health care, socio-economical problems and the cost of 
the treatment involved therein. To find out the trends and maternal outcomes in 
eclampsia in the region, a study was carried in a tertiary care unit i.e. Department 
of Gynaecology/Obstetrics, Bahawal Victoria Hospital (BVH), Bahawalpur, Pakistan, 
with the collaboration of Department of Pharmacology, King Saud University, Saudi 
Arabia. Methods: A total no. of 67 (n = 67) patients presented with eclampsia 
were assessed for maternal morbidity and mortality outcomes during the period 
of 6 months. A prospective study using a cross- sectional descriptive design was 
used. The patients were evaluated for various parameters that included biologi-
cal aging, type of complications, literacy level, socio-economical status, and par-
ity. Results: The calculated mean age of the patients was 25.69 ± 8.42 years. The 
incidence was found to be higher in the extremes of the reproductive life (bimodal 
variation), and during ante partum stage (55.2%) followed by postpartum (31.3%) 
and intrapartum period (13.4%). Among the patients examined, 44.8% were found 
with no formal education, 25.4% having primary education only, and 74.6% patients 
belonging to the lower socio-economic class. The incidence of eclampsia was higher 
in nulliparous women (58.2%) as compared to multiparous (31.3%) and grand mul-
tiparous women (10.4%). The overall complication to non-complication ratio was 
found to be 38.8% to 61.2%, with morbidity and mortality rate of 38.8 % and 13.4%, 
respectively. ConClusions: Keeping these finding in views, we may conclude that 
poor education, lack of effective health policies, and socioeconomic problems may 
contribute significantly to the morbidity and mortality associated with eclampsia 
in under developed regions.
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objeCtives: To conduct a thorough search of medical literature investigating 
the prevalence of cardiovascular comorbidities and its impact on health care 
costs, quality of life, and mortality among patients with type 2 diabetes mellitus 
(T2DM). Methods: Keywords and Medical Subject Headings were used to perform 
a search using MEDLINE, Cochrane, CINHAL Plus, and PsychINFO. Eligible studies 
were: published in English before June 2013, included cardiovascular or other 
comorbidities of T2DM, outcome researched was prevalence, economic burden, 
age of onset, quality of life or mortality of cardiovascular or other comorbidi-
ties, and the sample size was larger than 50. Results: Seventy-six studies and 
reports were used in this systematic review. Cardiovascular disease (CVD), includ-
ing hypertension, was the most prevalent complication of T2DM. Total health care 
costs of diabetic patients with CVD ranged from $10,450 to $14,414 per-person 
per-year in the United States. Quality of Life was found to be significantly lower 
in diabetes patients with cardiovascular complications, while mortality was found 
to be much higher than either illness alone. ConClusions: Prevalence of CVD 
is very high in T2DM patients with hypertension being the most prevalent. The 
additional cost burden due to CVD is also higher than any other comorbidity 
except End Stage Renal Disease (ESRD). Considering the much higher prevalence 
of CVD, compared with ESRD, increased cost due to CVD is likely to be higher than 
any other comorbidity at a population level. The quality of life was much lower in 
patients with CVD and diabetes, but not as low as in patients with comorbid pain-
ful neuropathy. Increased mortality was caused by the combination of diabetes and 
CVD. Cardiovascular complications in diabetes patients have a significant impact 
on the economic burden, quality of life, and the mortality rates. This research was 
funded by Bristol Myers Squibb.
(p-value < 0.0001). ConClusions: After adjusting for patient and hospital factors, 
hospital quality scores (both AMI and HF) were not strongly associated with the large 
amounts some hospitals charge beyond the standard reimbursement amount. The 
lack of strong associations suggests that either: (1) quality scores were not indica-
tors of hospital resource utilization, or (2) hospital charges were not driven by the 
expenses incurred as a result of providing high quality services, furthering the 
argument for increased cost transparency from health care providers.
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objeCtives: To characterize treatment patterns and health care resource utilization 
among adults diagnosed with non-valvular atrial fibrillation (NVAF) at the Social 
Security system (EsSalud) in Peru. Methods: Observational retrospective study 
based on medical chart review from the National Cardiovascular Institute (INCOR). 
The study included patients over 18 years of age, with a confirmed diagnosis of 
NVAF based on physician diagnosis and ICD-10 code, treated at INCOR NVAF in 
2011, allowing for a minimum potential follow-up of one year. Clinical study enroll-
ment or AF patients with valvular origin were excluded. For each eligible patient, 
information on patient and disease characteristics, treatments received, clinical 
outcomes, and AF-related health care resource utilization was captured. Patients 
were randomly selected from an electronic database until the predetermined sam-
ple size of 83 eligible patients was met. Results: The study population median 
age was 68.8 years, 66.3% were male. CHADS2 distribution was: 0-7.2%, 1–18.1%, 
2-18.1%, 3–32.5%, 4–18.1%, 5–6 % and 6-0%. 89.2% of patients with NVAF received 
at least one prescription during follow-up; distribution according to drug classes: 
77.0% heart rate control, 75.7% antiplatelets, 60.8% antihypertensives, 50.3% vitamin 
K antagonists and 44.6% anti-arrhythmic. A median of 30.2 diagnostic tests includ-
ing electrocardiograms and INR tests were performed per patient (range: 1 - 144). 
Twenty-three percent of patients had at least one procedure with implantation of 
a pacemaker being the most frequent procedure, followed by AV node ablation. 
30% of patients were hospitalized at least once during the study follow up period. 
Median hospital stay was 12.6 days (range:1-115). ConClusions: NVAF manage-
ment is heterogeneous at INCOR, particularly for rhythm control, anticoagulation 
monitoring, and the utilization of anticoagulant therapy.
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objeCtives: Compare the comorbidities and health care resource utilization of 
chronic plaque psoriasis compared to a matched control cohort in a large, Canadian, 
real-world dataset. Methods: This was an observational, retrospective study of 
patients ≥ 18 years who, between 2008 and 2012 received a diagnosis of psoriasis 
and at least 1 treatment. Data were retrieved from the Southwestern Ontario (SWO) 
database, which is a representative primary care database of over 325,000 unique 
patient records in Ontario, Canada. Comorbidities and health resource utilization 
were recorded in the patient chart as per their health care provider. A matched 
control cohort was constructed based on age, gender and ethnicity. Differences 
between psoriasis and control groups were compared using paired and independent 
samples t-tests. Results: A total of 7,776 patients in the SWO database (n= 325,618) 
had a diagnosis of psoriasis and received at least 1 treatment between January 1, 
2008 and December 31, 2012. Of these, 85% had chronic plaque psoriasis. Over half 
of patients with chronic plaque psoriasis were diagnosed with hypertension (61%, 
similar in the control group), 11% had diabetes (vs 7% in control group), 4% had 
depression and/or anxiety disorders (vs 1%), 6% had insomnia (vs 1%). Thirty-two 
percent (32%) were overweight and 24% were obese (vs 27% and 19%, respectively). 
Patients with moderate to severe plaque psoriasis (28%) were more likely to visit 
their family physician than the control group (9 vs 3 visits per year, respectively). 
These patients missed more days of work than the control (11 vs 4, respectively) and 
recorded more work absences (2 vs 0.03 absence notes per year). ConClusions: 
Chronic plaque psoriasis is a significant health condition and is associated with 
higher rates of comorbidity and use of health services in Canada, especially in 
patients with a moderate-severe condition.
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objeCtives: Few studies have assessed racial/ethnic and gender differences in 
diabetes-related complications, health care resource utilization (HRU) and costs in 
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objeCtives: The effectiveness of endoscopic screening for gastric cancer has been 
continually evaluated; however, only a few studies have reported its effectiveness. 
Notably morality reduction from cancer screening has not yet been rigorously evalu-
ated in survival analyses, but an important requirement for cancer screening is 
improving survival. We performed survival analysis for gastric cancer detected by 
endoscopic screening and compared the results with those of survival analysis for 
gastric cancer detected by radiographic screening and outpatients. Methods: The 
subjects of our study were selected from gastric cancer cases registered in 4 cities 
in the Tottori Cancer Registry from 2001 to 2006. The target age group was defined 
as the age in which gastric cancer was diagnosed from 40 to 79 years. Follow-up 
was continued from the date of diagnosis to the time death from gastric cancer or 
up to December 31, 2011. The survival of 3 groups at 5 and 10 years were compared 
using the Kaplan-Meier method with the log-rank test. Results: There were 347 
subjects selected for endoscopic screening, 166 for radiographic screening, and 980 
as outpatients. The 5-year survival rates were follows: 91.2 ± 1.5% (95% CI: 87.6-93.8) 
for endoscopic screening, 84.3 ± 2.9% (77.7-89.1) for radiographic screening, and 66.0 
± 1.6% (62.8-68.9) for outpatients. The 10-year survival rates were follows: 88.5 ± 2.0% 
(83.9-91.9) for endoscopic screening, 80.1 ± 3.6% (71.9-86.2) for radiographic screen-
ing, and 64.6 ± 1.6% (61.3-67.6) for outpatients. The survival rates were significantly 
different in the 3 groups (P < 0.001). ConClusions: The survival rate was higher 
for endoscopic screening than those for radiographic screening and outpatients. 
Since a high survival rate is mainly affected by lead–time bias, the effectiveness of 
endoscopic screening should be further evaluated in term of mortality reduction 
by conducting large-scale and reliable studies.
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objeCtives: Screening for type 2 diabetes (DM) has peaked as a controversial issue 
given the publication of the recent Canadian guidelines and since the clinical trial 
evidence for the effectiveness of DM screening is lacking. Methods: A two-step 
evidence-based analysis was performed: 1) narrative review of international guide-
lines 2) systematic review of primary studies. MEDLINE, EMBASE, CINAHL, Wiley 
Cochrane, and Centre for Reviews and Dissemination (2008-2012) were used to iden-
tify primary studies comparing the effectiveness of DM screening to usual care. 
Randomized controlled trials and observational studies meeting inclusion criteria 
were meta-analyzed and the quality of evidence was evaluated using GRADE. A 
cost analysis was developed using Ontario claims data and estimating the down-
stream health care costs in Canadian dollars of screening in Ontario. Results: Eight 
guidelines and six studies from 2,780 citations were identified. The recommenda-
tions for universal screening or screening for low to moderate risk individuals were 
heterogeneous, not shown for high or very high risk individuals. The guidelines 
consistently recommended screening for the latter. Screening was associated with 
a lower likelihood of retinopathy (RR: 0.54, 95% CI: 0.32-0.92) and lower absolute % 
HbA1c (MD: -0.32, 95% CI: -0.53, -0.11). Screening was not linked to increased anxi-
ety or false reassurance. One large RCT showed no beneficial effect of screening on 
long-term mortality outcomes. Two observational studies meta-analyzed showed 
no beneficial effect of screening for neuropathy and nephropathy. The quality of 
evidence was moderate to very low. Estimated cost savings is $150.4 million dollars 
using established parameters, with a range of cost savings as low as $16.7 up to 
$280.4 million dollars in sensitivity analysis. ConClusions: Despite its widespread 
acceptance, the evidence for the long-term effectiveness of DM screening is lacking. 
Further clinical and cost analysis in Canada is needed for short-term outcomes to 
help clarify the issue.
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objeCtives: To perform a systematic review to evaluate the quality of anticoagu-
lation control in outpatient pharmacist-managed anticoagulation services (PMAS) 
compared to routine medical care (RMC). Methods: We searched MEDLINE, 
SCOPUS, EMBASE, IPA, CINAHL, Cochrane CENTRAL, with language restriction to 
English. Two authors independently reviewed each study and extracted data for all 
outcomes using a standardized form, with any disagreement resolved by a third 
author. The primary outcome was the quality of warfarin-related anticoagulation 
management using time in therapeutic range (TTR) as an indicator. Warfarin-related 
bleeding, thrombotic events and resource utilization were assessed as secondary 
outcomes. Results: Of 155 articles identified, 23 articles met the criteria for final 
review. Of these, three studies were RCTs and twenty were observational studies. 
Most studies were conducted between year 2000 to 2013 (N= 18, 78%), and study 
follow-up ranged from six to twelve months (N= 13, 57%). Among studies that 
reported patients’ age, the average age ranged from 46 to 80.5 years, and was simi-
lar between PMAS and RMC groups. The majority of patients were treated for atrial 
fibrillation and venous thrombosis. Quality of anticoagulation control was better in 
the PMAS group compared to RMC, as indicated by higher TTRs in the majority of 
the studies (N= 21, 91%). Clinical outcomes were also favorable in the PMAS group 
as evidenced by lower risk of major bleeding (N= 10 of 14, 71%) or thromboembolic 
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objeCtives: Evidence from recent studies on statin treatment intensity for second-
ary prevention supports targeting lower low-density lipoprotein (LDL) levels through 
higher intensity statin treatment. This study aims to assess whether achievement 
of the lower LDL threshold is associated with a reduction in cardiovascular out-
comes. Methods: Retrospective cohort study of adult members of a large health 
fund with pre-existing ischemic heart disease (IHD) treated with statins for at least 
one year during 2006-2010, and with a routine, fasting serum LDL test measures. The 
incidence of the composite Major Adverse Cardiac Events (MACE) was compared 
between three patient groups according to their achieved LDL: (> 70·1-100mg/dl 
(Moderate) vs. > 100·1-130mg/dl (High), and > 70·1-100mg/dl (Moderate) vs. ≤ 70mg/
dl (Low)). Results: Of 52,177 patients treated with statins, 11,647 had an achieved 
LDL (post-statin treatment) of 70mg/dl or below, 29,097 between 70.1-100mg/dl and 
11,433 between 100·1-130mg/dl. Mean follow-up time from achieved LDL to MACE 
was 3·6 years (±1·5), with 10,955 subjects incurring a MACE during follow-up. LDL 
levels 70·1-100mg/dl compared to 100-130mg/dl were associated with a significant 
8% reduction in the incidence of MACE (hazard ratio [HR]= 0·92 [95% CI, 0·88-0·97; 
p= 0·001]), while ≤ 70 mg/dl compared to 70·1-100mg/dl was not (HR= 0·98 [95% CI, 
0·93-1·03; p= 0·374]). Results remained consistent in propensity score–adjusted Cox 
regression, a sensitivity analysis, and in a sub-group analysis, with no demonstrated 
advantage in MACE outcomes for achieved LDL levels ≤ 70mg/dl. ConClusions: 
Among a real-world population of IHD patients adherent to their statin treatment, 
achieving LDL levels below 100mg/dl is associated with significant clinical benefit, 
whereas no additional benefit is gained by achieving LDL levels below 70mg/dl.
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objeCtives: To describe the natural history of metastatic prostate cancer in 
patients treated with androgen deprivation therapy (ADT) or orchiectomy in clini-
cal practice. Methods: Newly diagnosed prostate cancer patients (2004-2010) 
treated with ADT/orchiectomy were identified from the Henry Ford Health System 
tumor registry. Patients were followed through July 31, 2012. Data on disease pro-
gression (rising prostate-specific antigen [PSA] and presence of metastases) were 
collected from medical records and automated data. Time from initial diagnosis 
to metastases was determined by Kaplan-Meier analyses. Results: We iden-
tified 702 patients; 58% ≥ 70 years and 50% African American; 56% of patients 
were initially diagnosed at stage II, 10% at stage III, 22% at stage IV, and 12% had 
missing/unknown stages. Three percent received orchiectomy; 97% received ADT. 
Comprehensive data on testosterone levels were not available. During follow-
up, an additional 8% of patients progressed to metastatic disease (N= 207): 52% 
(107) had evidence of postcastration disease progression (17% rising PSA, 28% 
presence of ≥ 2 new bone metastases, 55% met both criteria). Bone was the most 
common site, occurring in 74% of metastatic patients; 59% of metastatic patients 
developed bone mestastases to spine. Other metastatic sites included distant 
lymph nodes (12%), lung (8%), central nervous system (7%), and other (14%). Mean 
follow-up time was 3.8 years. Kaplan-Meier analysis indicated that by 5 years 
after initial diagnosis, 13% of stage II and 36% of stage III patients developed 
metastases. ConClusions: While the incidence of cancer is routinely collected 
via registries, information on progression or recurrence is sparse. This study is 
one of few to present information on the natural history and disease progression 
of ADT/orchiectomy-treated prostate cancer in a clinical setting. In this study, we 
found 30% of patients were diagnosed with or progressed to metastatic disease. 
This assessment of medical need may inform future resource planning.
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objeCtives: Objective To assess the diagnostic and clinical value of anti-mutated 
citrullinated vimentin (anti-MCV) antibody for rheumatoid arthritis (RA) via com-
paring with rheumatoid factors (RF) and anti-cyclic citrullinated peptide antibodies 
(anti-CCP). Methods: Anti-MCV and anti-CCP were determined using enzyme-
linked immunosorbent assay (ELISA), and meanwhile, the RF was detected in 88 
patients with RA and 16 patients with other rheumatic diseases. Receiver operating 
characteristic (ROC) curve was operated to calculate the areas under the curve of RF, 
anti-CCP and anti-MCV, the max Youden indexes were also calculated to determine 
the optimum testing threshold and the corresponding sensitivity and specificity, 
the diagnostic significance of RF, anti-CCP and anti-MCV in RA were analyzed. The 
correlation of erythrocyte sedimentation rate (ESR) and anti-MCV, and C reactive 
protein (CRP) and anti MCV were evaluated by linear-regression analysis. Results: 
The areas under the curve of RF, anti-CCP and anti-MCV were 0.775, 0.847 and 
0.873, respectively. The max Youden indexes of RF, anti-CCP and anti-MCV were 
0.534, 0636 and 0.71, respectively, and the corresponding sensitivity and specificity 
were 78.4% and 75%, 63.6% and 100%, and 77.3% and 93.7%, respectively. A correla-
tion between ESR and anti-MCV antibody, and CRP and anti-MCV antibody levels 
was observed. ConClusions: The sensitivity of anti-MCV is higher compared 
to anti-CCP and is comparable to RF, and its specificity is higher than that of RF. 
Consequently, anti-MCV can be served as a diagnostic index for RA and its expres-
sion is associated with disease activity of RA.
